The ability of p66KO NSCs to evade apoptosis and continue differentiation under sustained MEK inhibition highlights the potential of targeting p66Shc to preserve NSC viability in neurodegenerative diseases or brain injuries where growth factor signaling may be compromised. This evidence concerns the gene MAP2K7 and neurodegenerative disease.